No Detail Found!

Combination Treatment with Iodine 125 Seeds Implant and Systemic Therapy vs. Systemic Therapy Alone for Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

Author(s)
Huzi Li Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Wentao Li Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Libo Zhang Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Wenyan Fang Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Hong Zhang Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Abstract
Combination treatment with iodine 125 seeds implant and systemic therapy in patients with non-small-cell lung cancer (NSCLC) is a promising treatment practice. The present study aimed to assess the relative e cacy and toxicity of combination treatment versus systemic therapy alone in patients with NSCLC. Databases including PubMed, EBSCO, Web of Science, EMBASE, Cochrane Library, CNKI, and WanFang were searched for relevant randomised controlled trials (RCTs). Risk ratios (RR) were obtained for evaluating indicators in the present meta-analysis including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), overall response rate (ORR), disease control rate (DCR), one-year and two-year overall survival (OS) rate and complications. A total of 17 eligible RCTs incorporating 1315 patients who underwent combination treatment or systemic therapy alone were ultimately included in this meta-analysis based on our selection criteria. The results showed that CR (RR = 1.89, 95% con dence interval [CI]: 1.53 - 2.33, p <0.001), PR (RR = 1.28, 95%CI: 1.12 - 1.46, p = 0.0002), ORR (RR = 1.46, 95%CI: 1.34 - 1.58, p <0.001), DCR (RR = 1.11, 95%CI: 1.04 - 1.18, p = 0.001), two-year OS (RR = 1.52, 95% CI: 1.30 - 1.77, p <0.001) were higher and SD (RR = 0.53, 95%CI: 0.42 - 0.66, p <0.001) and PD (RR = 0.39, 95%CI: 0.29 - 0.55, p <0.001) were lower in the combination treatment group than in control group. Meanwhile, there was no signi cant di erence in one-year OS (RR = 1.13, 95% CI: 0.98-1.31, p = 0.10). In terms of adverse events, the combination therapy signi cantly increased the incidence of pneumothorax (RR = 4.91, 95% CI: 2.63 9.17, p <0.001); however, no signi cant di erences were found in the incidence of myelosuppression and gastrointestinal symptoms. Combination treatment with iodine 125 seeds implant and systemic therapy can signi cantly improve clinical response and prolong two-year OS in NSCLC patients without increasing the incidence of myelosuppression and gastrointestinal symptoms, except pneumothorax.
Publication Details
Page(s) 88-95
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
NSCLC, systemic therapy, Brachytherapy, Radioactive seeds
0

Citations

0

Downloads

61

Views